Soligenix (SNGX) Other Non-Current Liabilities (2012 - 2016)
Soligenix's (SNGX) quarterly Other Non-Current Liabilities came in at $1.3 million in Q3 2016, down 38.08% YoY from $2.1 million in Q4 2015, and up 15.35% on a QoQ basis from $1.1 million in Q2 2016.
Soligenix (SNGX) Other Non-Current Liabilities (2012 - 2016) Analysis & Trends
Soligenix (SNGX) has 5 years of Other Non-Current Liabilities data on file, last reported at $1.3 million in Q3 2016.
- Quarterly Other Non-Current Liabilities fell 38.08% year-over-year to $1.3 million in Q3 2016, while the trailing twelve-month figure through Sep 2016 was $1.3 million (down 38.08% YoY) and the FY2015 annual result came in at $2.4 million, down 35.77% from the prior year.
- Other Non-Current Liabilities advanced to $1.3 million in Q3 2016, from $1.1 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $10.0 million in Q3 2013 to a low of $1.1 million in Q2 2016.
- A 5-year average of $5.0 million and a median of $5.2 million in 2015 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2013 — Other Non-Current Liabilities soared 206.38% — and 2016, when it tumbled 81.48%.
- Tracing SNGX's Other Non-Current Liabilities over 5 years: stood at $2.7 million in 2012, then soared by 206.38% to $8.2 million in 2013, then plunged by 53.89% to $3.8 million in 2014, then plunged by 35.77% to $2.4 million in 2015, then plunged by 45.57% to $1.3 million in 2016.
- The last three Other Non-Current Liabilities figures came in at $1.3 million (Q3 2016), $1.1 million (Q2 2016), and $1.7 million (Q1 2016), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | 1.32 Mn |
| Jun 30, 2016 | 1.15 Mn |
| Mar 31, 2016 | 1.67 Mn |
| Dec 31, 2015 | 2.43 Mn |
| Sep 30, 2015 | 2.14 Mn |
| Jun 30, 2015 | 6.20 Mn |
| Mar 31, 2015 | 5.15 Mn |
| Dec 31, 2014 | 3.79 Mn |
| Sep 30, 2014 | 7.43 Mn |
| Jun 30, 2014 | 8.77 Mn |
| Mar 31, 2014 | 9.52 Mn |
| Dec 31, 2013 | 8.22 Mn |
| Sep 30, 2013 | 9.98 Mn |
| Jun 30, 2013 | 5.18 Mn |
| Dec 31, 2012 | 2.68 Mn |